SARS-CoV-2 (COVID-19) Nucleocapsid (N) Recombinant Protein
| Code | Size | Price |
|---|
| PSI-10-080-0.1mg | 0.1mg | £642.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Shipping:
blue ice or RT
Storage:
We recommended to store this recombinant protein as received at 2-8˚C for up to one month. For longer-term storage, aseptically aliquot in working volumes without diluting and store at -80˚C. Avoid Repeated Freeze Thaw Cycles.
Documents
Further Information
Application Note:
ELISA, WB
Background:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. The NTD of SARS-CoV-2 does not bind to ACE2 6, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties 7 and might play a role in the conformational change of S2 required for membrane fusion 8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients 9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV 10.
Background References:
- Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020.
- Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020.
- Wrapp D, Wang N, Corbett KS, et al. bioRxiv. 2020.
- Walls AC, Park YJ, Tortorici MA, et al. Cell. 181(2):281-292.e6. 2020.
Buffer:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 with no calcium, magnesium, or preservatives.
Concentration:
0.5 mg/ml
NCBI Official Name:
nucleocapsid protein
NCBI Organism:
Severe acute respiratory syndrome coronavirus 2
Physical State:
Liquid
Predicted Molecular Weight:
The predicted molecular weight of Recombinant SARS-CoV-2, Nucleocapsid (N) Protein is Mr 47 kDa.
Protein Accession #:
QHO62115
Purity:
>95% by SDS Page
Recombinant Protein Sequence:
#N/A
Source:
HEK293 cells